Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLTAGE: Nivolumab after Preoperative CRT in Rectal Cancer
NCT02948348Phase 2Unknown
- Sponsor
- Takayuki Yoshino
- Start
- Oct 2016
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in rectal cancer (5 arms), sponsored by Takayuki Yoshino. Primary endpoint: Pathological Complete Response at 1 year. Status: unknown.
02
Drugs
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02948348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948348.